Institution
American College of Rheumatology
Nonprofit•Atlanta, Georgia, United States•
About: American College of Rheumatology is a nonprofit organization based out in Atlanta, Georgia, United States. It is known for research contribution in the topics: Guideline & Population. The organization has 141 authors who have published 117 publications receiving 33521 citations.
Topics: Guideline, Population, Vasculitis, Rheumatology, Health care
Papers published on a yearly basis
Papers
More filters
••
American College of Rheumatology1, Cleveland Clinic2, Stanford University3, University of Colorado Hospital4, University of Calgary5, National Institutes of Health6, Mayo Clinic7, University of Kentucky8, University of Illinois at Chicago9, Harvard University10, Johns Hopkins University11, SUNY Downstate Medical Center12, University of California, San Diego13
TL;DR: Criteria for the classification of hypersensitivity vasculitis were developed by comparing 93 patients who had this disease with 714 control patients with other forms of vasculopathy, finding that the presence of 3 or more of these criteria was associated with a sensitivity of 71.0% and a specificity of 83.9%.
Abstract: Criteria for the classification of hypersensitivity vasculitis were developed by comparing 93 patients who had this disease with 714 control patients with other forms of vasculitis. For the traditional format classification, 5 criteria were selected: age greater than 16 at disease onset, history of taking a medication at onset that may have been a precipitating factor, the presence of palpable purpura, the presence of maculopapular rash, and a biopsy demonstrating granulocytes around an arteriole or venule. The presence of 3 or more of these 5 criteria was associated with a sensitivity of 71.0% and a specificity of 83.9%. A classification tree was also constructed. The criteria appearing in the tree structure were the same as for the traditional format, except there were 2 pathology criteria: one required the presence of granulocytes in the wall of an arteriole or venule, and the other required the presence of eosinophils in the inflammatory exudate. The classification tree was associated with a sensitivity of 78.5% and a specificity of 78.7%.
244 citations
••
TL;DR: The American College of Rheumatology Subcommittee on Classification of Vasculitis of the Diagnostic and Therapeutic Criteria Committee developed classification criteria for 7 forms of vasculitis: polyarteritis nodosa, Churg-Strauss syndrome, Wegener's granulomatosis, hypersensitivity vasculopathy, Henoch-Schönlein purpura, giant cell (temporal) arteritis, and Takayasu arteritis.
Abstract: The American College of Rheumatology Subcommittee on Classification of Vasculitis of the Diagnostic and Therapeutic Criteria Committee developed classification criteria for 7 forms of vasculitis: polyarteritis nodosa, Churg-Strauss syndrome, Wegener's granulomatosis, hypersensitivity vasculitis, Henoch-Schonlein purpura, giant cell (temporal) arteritis, and Takayasu arteritis. The data collection methods, quality control, and analytic procedures used to derive the classification rules are discussed herein.
238 citations
••
Seattle Children's1, Cincinnati Children's Hospital Medical Center2, University of Alabama at Birmingham3, McMaster University4, Children's Mercy Hospital5, National Institutes of Health6, University of Toronto7, Roy J. and Lucille A. Carver College of Medicine8, Virginia Commonwealth University9, University of British Columbia10, Columbia University Medical Center11, Brigham and Women's Hospital12, Medical University of South Carolina13, Duke University14, Boston Children's Hospital15, American College of Rheumatology16, ECRI Institute17
TL;DR: In this paper, the authors developed treatment recommendations for children with juvenile idiopathic arthritis manifesting with non-systemic polyarthritis, sacroiliitis, or enthesitis.
Abstract: Objective:
To develop treatment recommendations for children with juvenile idiopathic arthritis manifesting with non-systemic polyarthritis, sacroiliitis, or enthesitis.
193 citations
••
University of California, San Francisco1, Cleveland Clinic2, University of Kansas3, Mayo Clinic4, Columbia University5, McMaster University6, Northwestern University7, Emory University8, National Institutes of Health9, Children's Mercy Hospital10, University of Pennsylvania11, Johns Hopkins University12, Harvard University13, Boston Children's Hospital14, Vanderbilt University15, St Mary's Hospital16, University of Utah17, University at Buffalo18, University of South Florida19, American College of Rheumatology20
TL;DR: In this article, the authors provided evidence-based recommendations and expert guidance for the management of antineutrophil cytoplasmic antibody-associated vasculitis (AAV), including granulomatosis with polyangiitis (GPA), microscopic polyangisitis (MPA), and eosinophilic granulomas with polyanagliitis (EGPA), which required ≥70% consensus among the Voting Panel.
Abstract: Objective To provide evidence-based recommendations and expert guidance for the management of antineutrophil cytoplasmic antibody-associated vasculitis (AAV), including granulomatosis with polyangiitis (GPA), microscopic polyangiitis (MPA), and eosinophilic granulomatosis with polyangiitis (EGPA). Methods Clinical questions regarding the treatment and management of AAV were developed in the population, intervention, comparator, and outcome (PICO) format (47 for GPA/MPA, 34 for EGPA). Systematic literature reviews were conducted for each PICO question. The Grading of Recommendations Assessment, Development and Evaluation methodology was used to assess the quality of evidence and formulate recommendations. Each recommendation required ≥70% consensus among the Voting Panel. Results We present 26 recommendations and 5 ungraded position statements for GPA/MPA, and 15 recommendations and 5 ungraded position statements for EGPA. This guideline provides recommendations for remission induction and maintenance therapy as well as adjunctive treatment strategies in GPA, MPA, and EGPA. These recommendations include the use of rituximab for remission induction and maintenance in severe GPA and MPA and the use of mepolizumab in nonsevere EGPA. All recommendations are conditional due in part to the lack of multiple randomized controlled trials and/or low-quality evidence supporting the recommendations. Conclusion This guideline presents the first recommendations endorsed by the American College of Rheumatology and the Vasculitis Foundation for the management of AAV and provides guidance to health care professionals on how to treat these diseases.
174 citations
••
San Antonio Military Medical Center1, University of California, Los Angeles2, Harvard University3, Cleveland Clinic4, Hospital for Special Surgery5, University of Nebraska Medical Center6, Beth Israel Deaconess Medical Center7, Northwestern University8, Columbia University Medical Center9, Florida State University10, Nationwide Children's Hospital11, American College of Rheumatology12, University of Michigan13
TL;DR: To describe the character and composition of the 2015 US adult rheumatology workforce, evaluate workforce trends, and project supply and demand for clinical r heumatology care for 2015–2030, is described.
Abstract: Objective To describe the character and composition of the 2015 US adult rheumatology workforce, evaluate workforce trends, and project supply and demand for clinical rheumatology care for 2015-2030. Methods The 2015 Workforce Study of Rheumatology Specialists in the US used primary and secondary data sources to estimate the baseline adult rheumatology workforce and determine demographic and geographic factors relevant to workforce modeling. Supply and demand was projected through 2030, utilizing data-driven estimations regarding the proportion and clinical full-time equivalent (FTE) of academic versus nonacademic practitioners. Results The 2015 adult workforce (physicians, nurse practitioners, and physician assistants) was estimated to be 6,013 providers (5,415 clinical FTE). At baseline, the estimated demand exceeded the supply of clinical FTE by 700 (12.9%). By 2030, the supply of rheumatology clinical providers is projected to fall to 4,882 providers, or 4,051 clinical FTE (a 25.2% decrease in supply from 2015 baseline levels). Demand in 2030 is projected to exceed supply by 4,133 clinical FTE (102%). Conclusion The adult rheumatology workforce projections reflect a major demographic and geographic shift that will significantly impact the supply of the future workforce by 2030. These shifts include baby-boomer retirements, a millennial predominance, and an increase of female and part-time providers, in parallel with an increased demand for adult rheumatology care due to the growing and aging US population. Regional and innovative strategies will be necessary to manage access to care and reduce barriers to care for rheumatology patients.
160 citations
Authors
Showing all 142 results
Name | H-index | Papers | Citations |
---|---|---|---|
Anthony S. Fauci | 185 | 960 | 133535 |
David T. Felson | 153 | 861 | 133514 |
Peter Tugwell | 129 | 948 | 125480 |
Marc C. Hochberg | 127 | 691 | 87268 |
Frederick Wolfe | 119 | 417 | 101272 |
Daniel E. Furst | 109 | 643 | 59748 |
Daniel H. Solomon | 100 | 623 | 38921 |
Claire Bombardier | 100 | 295 | 61805 |
James F. Fries | 100 | 369 | 83589 |
Theodore Pincus | 97 | 420 | 46012 |
Elie A. Akl | 95 | 482 | 58031 |
Matthew H. Liang | 93 | 339 | 53685 |
Sherine E. Gabriel | 91 | 273 | 63492 |
Michael E. Weinblatt | 86 | 455 | 44442 |
Gene G. Hunder | 86 | 244 | 61920 |